alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM ACRES GAMING
INCORPORATED FORM 10-Q FOR THE QUARTER ENDED DECEMER 31, 1997 AND IS QUALIFIED
IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          JUN-30-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                       9,846,000
<SECURITIES>                                         0
<RECEIVABLES>                                2,986,000
<ALLOWANCES>                                  (206,000)
<INVENTORY>                                  3,961,000
<CURRENT-ASSETS>                            16,865,000
<PP&E>                                       5,288,000
<DEPRECIATION>                               2,595,000
<TOTAL-ASSETS>                              20,023,000
<CURRENT-LIABILITIES>                        2,654,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                  4,948,000
<COMMON>                                    19,593,000
<OTHER-SE>                                  (7,172,000)
<TOTAL-LIABILITY-AND-EQUITY>                20,023,000
<SALES>                                      9,765,000
<TOTAL-REVENUES>                             9,765,000
<CGS>                                        5,677,000
<TOTAL-COSTS>                                5,897,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                            (253,000)
<INCOME-PRETAX>                             (1,556,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,566,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                (1,566,000)
<EPS-PRIMARY>                                     (.18)<F1>
<EPS-DILUTED>                                     (.18)<F1>
<FN>
<F1>THIS INFORMATION HAS BEEN PREPARED IN ACCORDANCE WITH SFAS NO. 128. BASIC AND
DILUTED EPS HAVE BEEN ENTERED IN PLACE OF PRIMARY AND FULLY DILUTED EPS,
RESPECTIVELY.
</FN>
        

</TABLE>
Editorial Note on Part 173
Editorial Note: Nomenclature changes to part 173 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; and 81 FR 49896, July 29, 2016.

§ 173.150 Milk-clotting enzymes, microbial. Milk-clotting enzyme produced by pure-culture fermentation process may be safely used in the production of cheese in accordance with the following prescribed conditions: ( a ) Milk-clotting enzyme is derived from one of the following organisms by a pure-culture fermentation process: ( 1 ) *Endothia parasitica* classified as follows: Class, Ascomycetes; order, Sphaeriales; family, Diaporthacesae; genus, *Endothia;* species, *parasitica.*
( 2 ) *Bacillus cereus* classified as follows: Class, Schizomycetes; order, Eubacteriales; family, Bacillaceae; genus, *Bacillus;* species, *cereus* (Frankland and Frankland).
( 3 ) *Mucor pusillus* Lindt classified as follows: Class, Phycomycetes; subclass, Zygomycetes; order, Mucorales; family, Mucoraceae; genus, *Mucor;* species, *pusillus;* variety, *Lindt.*
( 4 ) *Mucor miehei Cooney et Emerson* classified as follows: Class, Phycomycetes; subclass, Zygomycetes; order, Mucorales; family, Mucoraceae; genus, *Mucor;* species, *miehei;* variety, *Cooney et Emerson.*
( 5 ) *Aspergillus oryzae* modified by recombinant deoxyribonucleic (DNA) techniques to contain the gene coding for aspartic proteinase from *Rhizomucor miehei* var. *Cooney et Emerson* as defined in paragraph (a)(4) of this section, and classified as follows: Class, Blastodeuteromycetes (Hyphomycetes); order, Phialidales (Moniliales); genus, *Aspergillus*; species *oryzae.*
( b ) The strains of organism identified in paragraph (a) of this section are nonpathogenic and nontoxic in man or other animals.
( c ) The additive is produced by a process that completely removes the generating organism from the milk-clotting enzyme product.
( d ) The additive is used in an amount not in excess of the minimum required to produce its intended effect in the production of those cheeses for which it is permitted by standards of identity established pursuant to section 401 of the Act.
[42 FR 14526, Mar. 15, 1977; 42 FR 56728, Oct. 28, 1977, as amended at 62 FR 59284, Nov. 3, 1997]
#### § 26.36 Listing of CAB's.

Each party shall designate conformity assessment bodies (CAB's) to participate in confidence building activities by transmitting to the other party a list of CAB's which meet the criteria for technical competence and independence, as identified in appendix A of this subpart. The list shall be accompanied by supporting evidence. Designated CAB's will be listed in appendix D of this subpart for participation in the confidence building activities once confirmed by the importing party. Nonconfirmation would have to be justified based on documented evidence.
§ 520.2340 Tepoxalin. ( a ) *Specifications.* Each tablet contains 30, 50, 100, or 200 milligrams (mg) tepoxalin.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* 10 mg per kilogram (/kg) daily; or 20 mg/kg on the initial day of treatment, followed by 10 mg/kg daily.
( 2 ) *Indications for use.* For the control of pain and inflammation associated with osteoarthritis.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[68 FR 34795, June 11, 2003]
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY INFORMATION EXTRACTED FROM THE CONDENSED
FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                          67,666
<SECURITIES>                                         0
<RECEIVABLES>                                2,868,593
<ALLOWANCES>                                   351,000
<INVENTORY>                                  2,244,317
<CURRENT-ASSETS>                             6,721,691
<PP&E>                                       3,514,784
<DEPRECIATION>                               2,338,837
<TOTAL-ASSETS>                              17,732,288
<CURRENT-LIABILITIES>                        5,597,658
<BONDS>                                      1,106,562
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        12,977
<OTHER-SE>                                  11,015,091
<TOTAL-LIABILITY-AND-EQUITY>                17,732,288
<SALES>                                     16,925,477
<TOTAL-REVENUES>                            17,798,035
<CGS>                                        9,549,677
<TOTAL-COSTS>                                9,549,677
<OTHER-EXPENSES>                            10,185,453
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             273,005
<INCOME-PRETAX>                            (2,175,647)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (2,175,647)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (2,175,647)
<EPS-BASIC>                                      (.10)
<EPS-DILUTED>                                    (.10)


</TABLE>
IIB 

118TH CONGRESS 

2D SESSION H. R. 7480 

IN THE SENATE OF THE UNITED STATES 

DECEMBER 5, 2024 

Received; read twice and referred to the Committee on Banking, Housing, and 

Urban Affairs 

AN ACT 

To amend section 102(a)(20) of the Housing and Community 

Development Act of 1974 to require the exclusion of 

service-connected disability compensation when determining whether a person is a person of low and moderate 

income, a person of low income, or a person of moderate 

income, and for other purposes. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

HR 7480 RFS

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Disabled Veterans 

5 Housing Support Act’’. 

6 SEC. 2. SERVICE CONNECTED DISABILITY COMPENSATION. 

7 Section 102(a)(20) of the Housing and Community 

8 Development Act of 1974 (42 U.S.C. 5302(a)(20)) is 

9 amended by adding at the end the following: 

10 ‘‘(C) SERVICE-CONNECTED DISABILITY

11 COMPENSATION.—When determining whether a 

12 person is a person of low and moderate income, 

13 a person of low income, or a person of moderate 

14 income under this paragraph, a State, unit of 

15 general local government, or Indian tribe shall 

16 exclude any service-connected disability com17 pensation received by such person from the De18 partment of Veterans Affairs.’’. 

19 SEC. 3. REPORT. 

20 The Comptroller General of the United States shall, 

21 not later than 1 year after the date of the enactment of 

22 this Act, submit to the Congress a report that— 

23 (1) examines how service-connected disability 

24 compensation is treated for the purposes of deterVerDate Sep 11 2014 21:26 Dec 10, 2024 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H7480.RFS H7480

kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

HR 7480 RFS

1 mining eligibility for all programs administered by 

2 the Secretary of Housing and Urban Development; 

3 (2) identifies any instances where service-con4 nected disability compensation is treated in a man5 ner inconsistent with the amendment made by sec6 tion 2; and 

7 (3) with respect to each program administered 

8 by the Secretary of Housing and Urban Develop9 ment in which service-connected disability compensa10 tion is treated inconsistently, provides legislative rec11 ommendations relating to how such program could 

12 better serve veteran populations, and under-served 

13 communities. 

Passed the House of Representatives December 4, 

2024. 

Attest: KEVIN F. MCCUMBER, 

Clerk. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
§ 556.150 Chlortetracycline. ( a ) *Acceptable daily intake (ADI).* The ADI for total residue of tetracyclines including chlortetracycline, oxytetracycline, and tetracycline is 25 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerances for the sum of tetracycline residues are: ( 1 ) *Cattle.* ( i ) Liver: 6 ppm.
( ii ) Kidney and fat: 12 ppm.
( iii ) Muscle: 2 ppm.
( 2 ) *Chickens, turkeys, and ducks.* ( i ) Liver: 6 ppm.
( ii ) Kidney and fat: 12 ppm.
( iii ) Muscle: 2 ppm.
( iv ) Eggs: 0.4 ppm for chlortetracycline only.
( 3 ) *Sheep.* ( i ) Liver: 6 ppm.
( ii ) Kidney and fat: 12 ppm.
( iii ) Muscle: 2 ppm.
( 4 ) *Swine.* ( i ) Liver: 6 ppm.
( ii ) Kidney and fat: 12 ppm.
( iii ) Muscle: 2 ppm.
( c ) *Related conditions of use.* See §§ 520.441, 520.443, 520.445, 558.128, and 558.140 of this chapter.
§ 522.1890 Prednisone suspension. ( a ) *Specifications.* Each milliliter of suspension contains 10 to 40 milligrams (mg) of prednisone.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount* — ( i ) *Horses.* Administer 100 to 400 mg by intramuscular injection, repeating if necessary.
( ii ) *Dogs and cats.* Administer 0.25 to 1.0 mg per pound of body weight by intramuscular injection for 3 to 5 days or until a response is noted. Treatment may be continued with an orally administered dose.
( 2 ) *Indications for use.* It is used for conditions requiring an anti-inflammatory agent.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16194, Mar. 25, 2014]
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr.

, Chief Justice

Michael F. Cavanagh

Marilyn Kelly

Stephen J. Markm an Diane M. Hathaway

Mary Beth Kelly

Brian K. Zahra

, Justices

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

_________________________________________ Clerk November 20, 2012

h1113 

# Order

November 20, 2012

145674

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff

- Appellee,

v SC: 145674

COA: 309615

Kent CC: 04

- 004011

- FC

JAMES DONALD MOORE, 04

- 004013

- FC

Defendant

- Appellant.

_________________________________________/

On order of the Court, the application for leave to appeal the May 25, 2012 order

of the Court of Ap peals is considered, and it is DENIED, because the defendant’s motion

for relief from judgment is prohibited by MCR 6.502(G).
<PAGE>
                                                                    EXHIBIT 11.1



                                KERAVISION, INC.
                 STATEMENT OF COMPUTATION OF NET LOSS PER SHARE
                     (IN THOUSANDS, EXCEPT PER SHARE DATA)



                                               YEAR ENDED DECEMBER 31,
                                             1996        1995       1994
                                           ------------------------------
Net Loss................................   $(12,879)   $(7,106)   $(6,097)
                                           ==============================


Historical Net Loss per Share:
-----------------------------
Shares used in computation of net loss
 per share:
 Weighted average common shares
  outstanding...........................     12,342      6,829      1,467
 Shares related to Staff Accounting
  Bulletins Nos. 55, 64 and 83:
   Stock option grants..................         --         49         84
   Issuances of common stock............         --          1      1,474
                                           ------------------------------
                                             12,342      6,879      3,025
                                           ==============================
Historical net loss per share...........   $  (1.04)   $ (1.03)   $ (2.02)
                                           ==============================

Pro forma Net Loss per Share:
----------------------------
Shares used in computation of
 proforma net loss per share:
   Historical weighted average common
    shares per above...................                  6,879      3,025

   Assumed conversion of convertible
    preferred stock as of beginning
     of year...........................                  3,085      5,263

                                           -------------------------------

                                                         9,964      8,288
                                           ==============================
Pro forma net loss per share.........                  $ (0.71)   $ (0.74)
                                           ==============================
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               MAR-31-2000
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                   444868
<ALLOWANCES>                                         0
<INVENTORY>                                    5664174
<CURRENT-ASSETS>                               9393513
<PP&E>                                        12231524
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                25614068
<CURRENT-LIABILITIES>                          8854048
<BONDS>                                        4626616
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        498562
<OTHER-SE>                                    11634842
<TOTAL-LIABILITY-AND-EQUITY>                  25614068
<SALES>                                       12805628
<TOTAL-REVENUES>                              12805628
<CGS>                                          8218515
<TOTAL-COSTS>                                 14488402
<OTHER-EXPENSES>                                 72072
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              (1754846)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (1754846)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (1754846)
<EPS-BASIC>                                   (0.35)
<EPS-DILUTED>                                   (0.35)


</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE 
FINANCIAL STATEMENTS OF CYBEX COMPUTER PRODUCTS CORPORATION FOR THE SIX MONTHS
ENDED SEP-30-1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH 
FINANCIAL STATEMENTS.
</LEGEND>
<RESTATED>
<CIK> 0000946360
<NAME> CYBEX COMPUTER PRODUCTS CORPORATION
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          MAR-31-1997
<PERIOD-START>                             APR-01-1996
<PERIOD-END>                               SEP-30-1996
<EXCHANGE-RATE>                                      1
<CASH>                                           3,597
<SECURITIES>                                    30,683
<RECEIVABLES>                                    5,513
<ALLOWANCES>                                       165
<INVENTORY>                                      3,155
<CURRENT-ASSETS>                                41,315
<PP&E>                                           2,461
<DEPRECIATION>                                     679
<TOTAL-ASSETS>                                  45,412
<CURRENT-LIABILITIES>                            2,003
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             9
<OTHER-SE>                                      47,150
<TOTAL-LIABILITY-AND-EQUITY>                    45,412
<SALES>                                         15,478
<TOTAL-REVENUES>                                15,478
<CGS>                                            7,258
<TOTAL-COSTS>                                    7,258
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                    34
<INTEREST-EXPENSE>                                   4
<INCOME-PRETAX>                                  4,240
<INCOME-TAX>                                     1,537
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     2,703
<EPS-PRIMARY>                                     0.32
<EPS-DILUTED>                                     0.32
<FN>
WE HAVE CALCULATED EARNINGS PER SHARE AMOUNTS IN ACCORDANCE WITH FAS 128
"EARNINGS PER SHARE." WE HAVE ENTERED BASIC AND DILUTED AMOUNTS IN PLACE OF
PRIMARY AND FULLY DILUTED, RESPECTIVELY, AND REFLECT THE THREE-FOR-TWO STOCK
DIVIDEND EFFECTIVE APRIL 10, 1998.
</FN>
        

</TABLE>
§ 520.1443 Milbemycin oxime and lufenuron. ( a ) *Specifications.* ( 1 ) Tablets containing: 2.3 milligrams (mg) milbemycin oxime and 46 mg lufenuron, 5.75 mg milbemycin oxime and 115 mg lufenuron, 11.5 mg milbemycin oxime and 230 mg lufenuron, or 23 mg milbemycin oxime and 460 mg lufenuron.
( 2 ) Flavored tablets containing: 2.3 mg milbemycin oxime and 46 mg lufenuron, 5.75 mg milbemycin oxime and 115 mg lufenuron, 11.5 mg milbemycin oxime and 230 mg lufenuron, or 23 mg milbemycin oxime and 460 mg lufenuron.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) [Reserved]
( d ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* 0.5 mg milbemycin oxime and 10 mg lufenuron per kilogram of body weight, once a month.
( ii ) *Indications for use.* ( A ) For use in dogs and puppies for the prevention of heartworm disease caused by *Dirofilaria immitis,* for prevention and control of flea populations, for control of adult *Ancylostoma caninum* (hookworm), and for removal and control of adult *Toxocara canis, Toxascaris leonina* (roundworm), and *Trichuris vulpis* (whipworm) infections.
( B ) The concurrent use of flavored milbemycin oxime and lufenuron tablets described in paragraph (a)(2) of this section as in paragraph (d)(1)(ii)(A) of this section with nitenpyram tablets as in § 520.1510(d)(1) of this chapter is indicated to kill adult fleas and prevent flea eggs from hatching.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) [Reserved]
[62 FR 28629, May 27, 1997, as amended at 63 FR 41190, Aug. 3, 1998; 68 FR 51905, Aug. 29, 2003. Redesignated at 77 FR 47512, Aug. 9, 2012, as amended at 80 FR 18776, Apr. 8, 2015; 86 FR 13184, Mar. 8, 2021]
EXHIBIT 32.2








CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO


18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906


OF THE SARBANES-OXLEY ACT OF 2002








This certification is provided pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and accompanies the Quarterly Report on Form 10-Q (the “Form 10-Q”) for the quarter ended March 31, 2011 of Crimson Exploration Inc. (the “Issuer”).  The undersigned hereby certifies that the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Issuer.





Date:
May 12, 2011/s/ E. Joseph GradyName:
E. Joseph GradyTitle:
Senior Vice PresidentChief Financial Officer








A signed original of this written statement required by Section 906 has been provided to the Issuer and will be furnished to the Securities and Exchange Commission, or its staff, upon request.